Latest Conference Coverage

The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]

Chia-Chun Chiang, MD, associate professor of neurology at Mayo Clinic Rochester, discussed how AI-based ECG and imaging tools can aid in predicting stroke and cardiovascular outcomes in patients with migraine.

The chair of neurology at the University of South Carolina discussed findings from a study recently presented at AHS 2025 that linked migraine to autonomic dysfunction, increased risk of atrial fibrillation, and cardioembolic stroke. [WATCH TIME: 5 minutes]

The postdoctoral researcher at the Woolcock Institute of Medical Research highlighted EEG-based evidence supporting ALKS 2680's wake-promoting effects in patients with narcolepsy and idiopathic hypersomnia. [WATCH TIME: 3 minutes]

Fremanezumab shows significant long-term effectiveness in reducing migraine frequency and severity, enhancing patient outcomes in chronic and episodic cases.

The neurologist and headache specialist at the Montreal Neurological Clinic spoke about a recent national survey presented at AHS 2025 that revealed insightful patient perspectives in migraine. [WATCH TIME: 5 minutes]

Jennifer Robblee, MD, MSc, headache neurologist at the Barrow Neurological Institute, talked about an expert panel that developed a consensus definition for refractory migraine.

Nathaniel M. Schuster, MD, associate clinic director at the UC San Diego, talked about findings from a study of vaporized cannabis in treating patients with acute migraine presented at AHS 2025.

Laura Sebrow, PhD, a post doctoral neuropsychology fellow at North Shore University Hospital, discussed the relationship between patients’ reported cognitive difficulties and measurable cognitive performance during different migraine phases.

Omonigho Michael Bubu, MD, PhD, an associate professor of psychiatry, neurology, & population health at NYU Langone, discussed how OSA contributes to Alzheimer disease risk through race- and sex-specific mechanisms and neurodegenerative biomarkers.

Richard Bogan, MD, FCCP, FAASM, an associate clinical professor at the University of South Carolina School of Medicine, discussed a bevy of presentations from the 2025 SLEEP Annual Meeting highlighting the effects of once-nightly sodium oxybate.

Anita Shelgikar, MD, a clinical professor at the University of Michigan and president of the American Academy of Sleep Medicine, provided post-conference perspectives on the 2025 SLEEP meeting, giving clinicians insights on the latest in research and treatment updates.

Centessa Pharmaceuticals initiates Phase 1 study for ORX142, a novel orexin receptor agonist targeting neurological disorders, promising new treatment avenues.

The associate vice president of strategy and innovation at the National MS Society highlighted the measurable benefits of health and wellness coaching for individuals with multiple sclerosis. [WATCH TIME: 5 minutes]

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health discussed the effect of loneliness and social isolation on individuals living with multiple sclerosis.

The assistant professor of neurology at the Medical College of Wisconsin talked about the complexities of advanced multiple sclerosis, highlighting gaps in clinical trials and the need for individualized care strategies. [WATCH TIME: 3 minutes]

The neuropathologist at Mayo Clinic Florida discussed why EEG-based sleep biomarkers may help detect Alzheimer disease earlier and how they could enhance clinical trial design. [WATCH TIME: 3 minutes]

The chief executive officer of Restful Sleep MD emphasized the importance of tailoring pediatric sleep interventions to each family’s unique structure, values, and challenges. [WATCH TIME: 5 minutes]

The director of sleep health at Flinders University discussed the latest clinical advances in pharmacotherapy, precision treatment targets, and combination strategies for obstructive sleep apnea.

Deepa Burman, MD, FAASM, co-director of the Pediatric Sleep Evaluation Center at UPMC Children’s Hospital of Pittsburgh, discussed the potential contributors to pediatric insomnia and the role of a thorough assessment for effective management.

The director of the DMD Program at UMass Chan Medical School shared her experience at the 2025 CureDuchenne FUTURES National Conference, held May 22-25, in San Antonio, Texas. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending June 14, 2025. [WATCH TIME: 4 minutes]

The director of the Center for Brain and Mind Health at Yale University discussed new findings in thrombolytic therapy, stroke monitoring, neuroprotection, and imaging technologies presented at ESOC 2025. [WATCH TIME: 7 minutes]

Funke Afolabi-Brown, MD, FAASM, chief executive officer of Restful Sleep MD, discussed the potential role of family dynamics and individualized planning in the effective management of pediatric sleep disorders.

The neurosurgeon at Northwestern Medicine discussed diagnostic approaches, evolving treatment strategies, and the importance of timely referral in managing peripheral nerve injuries. [WATCH TIME: 3 minutes]

A new phase 2 study explores samelisant's potential to treat cataplexy in narcolepsy type 1, promising improved patient outcomes and safety.

New 5-year findings from the National RLS Opioid Registry presented at SLEEP 2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome.

Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]